文献速递骨软组织肉瘤与黑色素瘤

评估斯巴达利珠单抗联合达拉非尼和曲美替尼治疗BRAF V600突变不可切除或转移性黑色素瘤的随机III期试验

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
PubMed 文献 · J Clin Oncol · 2022-01-14

COMBI-i是一项III期随机试验,比较斯巴达利珠单抗联合达拉非尼和曲美替尼(sparta-DabTram)与安慰剂联合达拉非尼和曲美替尼(placebo-DabTram)在BRAF V600突变不可切除或转移性黑色素瘤患者中的疗效。主要终点研究者评估的无进展生存期未达到统计学显著差异,研究未达到主要终点;3级及以上治疗相关不良事件发生率在sparta-DabTram组为55%,高于安慰剂组的33%。

要点

  • sparta-DabTram组中位无进展生存期为16.2个月,placebo-DabTram组为12.0个月(HR 0.82,95%CI 0.66-1.03;P=0.042,单侧,未达显著)。
  • 客观缓解率在sparta-DabTram组为69%,placebo-DabTram组为64%。
  • 3级及以上治疗相关不良事件发生率在sparta-DabTram组为55%,placebo-DabTram组为33%。

核心结论

  • 研究未达到主要终点,结果不支持sparta-DabTram的一线广泛使用。
  • 进一步的生物标志物驱动研究可能识别可从免疫检查点抑制剂联合靶向治疗中获益的患者亚群。

研究设计与样本

  • COMBI-i是一项III期随机试验,评估斯巴达利珠单抗联合达拉非尼和曲美替尼(sparta-DabTram)对比安慰剂联合达拉非尼和曲美替尼(placebo-DabTram)在BRAF V600突变不可切除或转移性黑色素瘤患者中的疗效。
  • 患者接受斯巴达利珠单抗400 mg静脉注射每4周一次联合达拉非尼150 mg口服每日两次和曲美替尼2 mg口服每日一次,或安慰剂联合达拉非尼和曲美替尼。
  • 入组患者年龄≥18岁,患有不可切除或转移性BRAF V600突变黑色素瘤。
  • 主要终点为研究者评估的无进展生存期,总生存期为关键次要终点(ClinicalTrials.gov标识符:NCT02967692)。

主要发现

  • 数据截止日期为2020年7月1日,sparta-DabTram组中位无进展生存期为16.2个月(95%CI 12.7-23.9个月),placebo-DabTram组为12.0个月(95%CI 10.2-15.4个月),风险比(HR)为0.82(95%CI 0.66-1.03;P=0.042,单侧,未达显著)。
  • sparta-DabTram组客观缓解率为69%(183/267例),placebo-DabTram组为64%(170/265例)。
  • sparta-DabTram组3级及以上治疗相关不良事件发生率为55%(146/267例),placebo-DabTram组为33%(88/264例)。

临床怎么用

  • 研究结论指出,结果不支持sparta-DabTram的一线广泛使用。
  • 作者认为,进一步的生物标志物驱动研究可能识别可从免疫检查点抑制剂联合靶向治疗中获益的患者亚群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence suggesting that immune checkpoint inhibitors plus targeted therapy may improve treatment outcomes in patients with BRAF V600-mutant metastatic melanoma. COMBI-i is a phase III trial evaluating spartalizumab, an anti-programmed death receptor 1 antibody, in combination with dabrafenib and trametinib (sparta-DabTram), versus placebo plus dabrafenib and trametinib (placebo-DabTram) in patients with BRAF V600-mutant unresectable or metastatic melanoma. METHODS: Patients received spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily or placebo-DabTram. Participants were age ≥ 18 years with unresectable or metastatic BRAF V600-mutant melanoma. The primary end point was investigator-assessed progression-free survival. Overall survival was a key secondary end point (ClinicalTrials.gov identifier: NCT02967692). RESULTS: At data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-DabTram arm versus 12.0 months (95% CI, 10.2 to 15.4 months) in the placebo-DabTram arm (hazard ratio, 0.82 [95% CI, 0.66 to 1.03]; P = .042 [one-sided; nonsignificant]). The objective response rates were 69% (183 of 267 patients) versus 64% (170 of 265 patients), respectively. Grade ≥ 3 treatment-related adverse events occurred in 55% (146 of 267) of patients in the sparta-DabTram arm and 33% (88 of 264) in the placebo-DabTram arm. CONCLUSION: The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results. Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dummer R, Long GV, Robert C, et al. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022. PMID: 35030011. doi:10.1200/JCO.21.01601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。